AR006640A1 - Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido - Google Patents
Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituidoInfo
- Publication number
- AR006640A1 AR006640A1 ARP970101488A ARP970101488A AR006640A1 AR 006640 A1 AR006640 A1 AR 006640A1 AR P970101488 A ARP970101488 A AR P970101488A AR P970101488 A ARP970101488 A AR P970101488A AR 006640 A1 AR006640 A1 AR 006640A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- substituted
- halogen
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un procedimiento para la preparación de una sal de magnesio de un compuesto heterociclico sulfinilo-substituido que contiene una porción imidazoltal como en los compuestos de la fórmula (I) donde Ar es (II); Z es (III) y X es (IV), donde N en elinterior del anillo benceno de la porción bencimidazolsignifica que uno de los átomos substituídos con R7, R10 puede estar opcionalmente intercambiado con un átomo de nitrógeno sin ningún substituyente:R1, R2 y R3 son iguales o dif erentes y estánseleccionados entre hidrógeno, alquilo, alcoxi opcionalmente substituido con fluor, alcoxialcoxi dialquilaminopiperidina, morfolino, halógeno, fenilalquilo y fenilalcoxi; R4 y R5 son iguales o diferentes y están seleccionad os entre hidrógeno,alquilo y aralquiloR6 es hidrógeno, halógeno, trifluormetilo, alquilo y alcoxi; R7-R10 son iguales o diferentes y están seleccionados entre hidrógeno, alquilo, alcoxi, halógeno,haloalcoxi, alquilcaarbonilo, alcoxicarbonilo, oxaxol ilo,trifluoralquilo o grupos adyacentes R7-R10 para formar estructuras de anillo que pueden estaradicionalmente substituidas: R11 es hidrógeno o forma una cadena alquileno conjuntamente con R3 y R12 y R13 son iguales o diferentes y están seleccionadosentre hidrógeno, halógeno o alquilo o los grupos alquilo, grupos alcoxi y porciones de los mismos pueden ser de cadena recta o ramificada C2-C9 o puedencomprender grupos alquilo ciclicos, por ejemplo cicloalquilalquilo donde elheterociclo sulfinilo substituído de fórmula (I) se mezcla conjuntamente conuna base débil y una fuente de magnesio. Las sales preparadas por este procedimiento y las composiciones farmacéuticas que las contienen son útilescomo inhibidores de labomba de protones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9601598A SE508669C2 (sv) | 1996-04-26 | 1996-04-26 | Nytt förfarande |
Publications (1)
Publication Number | Publication Date |
---|---|
AR006640A1 true AR006640A1 (es) | 1999-09-08 |
Family
ID=20402358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970101488A AR006640A1 (es) | 1996-04-26 | 1997-04-14 | Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido |
Country Status (40)
Country | Link |
---|---|
US (1) | US6124464A (es) |
EP (1) | EP0897386B1 (es) |
JP (1) | JP4233115B2 (es) |
KR (1) | KR100468331B1 (es) |
CN (1) | CN1100776C (es) |
AR (1) | AR006640A1 (es) |
AT (1) | ATE222904T1 (es) |
BR (1) | BR9708829A (es) |
CA (1) | CA2251636C (es) |
CZ (1) | CZ295067B6 (es) |
DE (1) | DE69714987T2 (es) |
DK (1) | DK0897386T3 (es) |
DZ (1) | DZ2209A1 (es) |
EE (1) | EE03485B1 (es) |
EG (1) | EG23874A (es) |
ES (1) | ES2180981T3 (es) |
HK (1) | HK1016978A1 (es) |
HR (1) | HRP970210B1 (es) |
HU (1) | HUP9901798A3 (es) |
ID (1) | ID16685A (es) |
IL (1) | IL126716A (es) |
IS (1) | IS1984B (es) |
MA (1) | MA24143A1 (es) |
MY (1) | MY119011A (es) |
NO (1) | NO318850B1 (es) |
NZ (1) | NZ332154A (es) |
PL (1) | PL188824B1 (es) |
PT (1) | PT897386E (es) |
RS (1) | RS49718B (es) |
RU (1) | RU2163238C2 (es) |
SA (1) | SA97170759B1 (es) |
SE (1) | SE508669C2 (es) |
SI (1) | SI0897386T1 (es) |
SK (1) | SK282752B6 (es) |
TN (1) | TNSN97068A1 (es) |
TR (1) | TR199802156T2 (es) |
TW (1) | TW420676B (es) |
UA (1) | UA51699C2 (es) |
WO (1) | WO1997041114A1 (es) |
ZA (1) | ZA973153B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
IL142629A0 (en) * | 1998-11-18 | 2002-03-10 | Astra Ab | Improved chemical process and pharmaceutical formulation |
CA2290893C (en) * | 1999-11-16 | 2007-05-01 | Bernard Charles Sherman | Magnesium omeprazole |
CA2417311C (en) | 2000-08-04 | 2012-07-10 | Takeda Chemical Industries, Ltd. | Crystalline alkali metal salts of lansoprazole and their production and use |
CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
ATE363480T1 (de) | 2002-03-05 | 2007-06-15 | Astrazeneca Ab | Alkylammoniumsalze von omeprazol und esomeprazol |
DE10234617B4 (de) * | 2002-07-29 | 2013-04-04 | Nycomed Gmbh | Neues Salz von (S)-Pantoprazol |
TW200410955A (en) * | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
EP1556043A1 (en) * | 2002-10-22 | 2005-07-27 | Ranbaxy Laboratories, Ltd. | Amorphous form of esomeprazole salts |
US20040242642A1 (en) * | 2002-11-18 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Crystalline esomeprazole compounds and process for the preparation thereof |
JP2006514108A (ja) * | 2002-12-19 | 2006-04-27 | テバ ファーマシューティカル インダストリーズ リミティド | パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法 |
EP1606279A1 (en) * | 2003-02-28 | 2005-12-21 | Ranbaxy Laboratories, Ltd. | Polymorphs of s-omeprazole |
CL2004000983A1 (es) | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
WO2005012289A1 (en) * | 2003-07-17 | 2005-02-10 | Altana Pharma Ag | Novel salt of (r) - pantoprazole |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
SE0302382D0 (sv) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
SE0302381D0 (sv) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
ITMI20031813A1 (it) * | 2003-09-23 | 2005-03-24 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | Procedimento per la preparazione di pantoprazolo e suoi sali. |
WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
ES2246149B1 (es) * | 2004-07-02 | 2007-06-01 | Esteve Quimica, S.A. | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
US20060141054A1 (en) | 2004-10-25 | 2006-06-29 | Thomas Piccariello | Metal coordinated compositions |
US7799937B2 (en) | 2004-10-25 | 2010-09-21 | Synthonics, Inc. | Metal coordinated compositions |
US8779175B2 (en) * | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7553857B2 (en) | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
WO2007146341A2 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries Ltd. | Amorphous and crystalline forms of pantoprazole magnesium salt |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
EP2125783A2 (en) | 2007-02-21 | 2009-12-02 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
EP2195309A4 (en) * | 2007-10-08 | 2013-04-24 | Hetero Drugs Ltd | SALT POLYMORPHS OF THE ESOMEPRAZOLE |
EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
US20110207779A1 (en) * | 2010-02-25 | 2011-08-25 | Glenmark Generics Ltd | Process for the preparation of esomeprazole magnesium |
EP2426111A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
CN103467453A (zh) * | 2013-09-13 | 2013-12-25 | 上海海虹实业(集团)巢湖今辰药业有限公司 | 一种奥美拉唑镁原料药制备方法 |
CN106397399A (zh) * | 2015-07-29 | 2017-02-15 | 陕西合成药业股份有限公司 | 一种泮托拉唑镁的精制方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
GB8307865D0 (en) * | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
FI861772A (fi) * | 1985-05-07 | 1986-11-08 | Chemie Linz Ag | Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning. |
FI864138A (fi) * | 1985-10-16 | 1987-04-17 | Fisons Plc | Heterocykliska blandningar. |
WO1993006097A1 (en) * | 1991-09-20 | 1993-04-01 | Merck & Co., Inc. | Novel process for the preparation of anti-ulcer agents |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
PT1078628E (pt) * | 1994-07-08 | 2009-01-27 | Astrazeneca Ab | Forma de dosagem em comprimidos com unidades múltiplas |
-
1996
- 1996-04-26 SE SE9601598A patent/SE508669C2/sv not_active IP Right Cessation
-
1997
- 1997-03-29 SA SA97170759A patent/SA97170759B1/ar unknown
- 1997-04-14 ZA ZA9703153A patent/ZA973153B/xx unknown
- 1997-04-14 TW TW086104766A patent/TW420676B/zh not_active IP Right Cessation
- 1997-04-14 AR ARP970101488A patent/AR006640A1/es active IP Right Grant
- 1997-04-15 TN TNTNSN97068A patent/TNSN97068A1/fr unknown
- 1997-04-17 MA MA24558A patent/MA24143A1/fr unknown
- 1997-04-20 DZ DZ970056A patent/DZ2209A1/fr active
- 1997-04-21 HR HR970210A patent/HRP970210B1/xx not_active IP Right Cessation
- 1997-04-22 HU HU9901798A patent/HUP9901798A3/hu unknown
- 1997-04-22 RU RU98121016/04A patent/RU2163238C2/ru not_active IP Right Cessation
- 1997-04-22 ID IDP971342A patent/ID16685A/id unknown
- 1997-04-22 UA UA98105319A patent/UA51699C2/uk unknown
- 1997-04-22 EG EG32297A patent/EG23874A/xx active
- 1997-04-22 DK DK97921045T patent/DK0897386T3/da active
- 1997-04-22 CN CN97194114A patent/CN1100776C/zh not_active Expired - Fee Related
- 1997-04-22 SI SI9730402T patent/SI0897386T1/xx unknown
- 1997-04-22 AT AT97921045T patent/ATE222904T1/de active
- 1997-04-22 PL PL97329683A patent/PL188824B1/pl not_active IP Right Cessation
- 1997-04-22 WO PCT/SE1997/000674 patent/WO1997041114A1/en active IP Right Grant
- 1997-04-22 US US08/860,825 patent/US6124464A/en not_active Expired - Lifetime
- 1997-04-22 ES ES97921045T patent/ES2180981T3/es not_active Expired - Lifetime
- 1997-04-22 NZ NZ332154A patent/NZ332154A/en unknown
- 1997-04-22 CA CA002251636A patent/CA2251636C/en not_active Expired - Lifetime
- 1997-04-22 KR KR10-1998-0708556A patent/KR100468331B1/ko not_active IP Right Cessation
- 1997-04-22 EE EE9800363A patent/EE03485B1/xx not_active IP Right Cessation
- 1997-04-22 EP EP97921045A patent/EP0897386B1/en not_active Expired - Lifetime
- 1997-04-22 CZ CZ19983398A patent/CZ295067B6/cs not_active IP Right Cessation
- 1997-04-22 IL IL12671697A patent/IL126716A/xx not_active IP Right Cessation
- 1997-04-22 BR BR9708829A patent/BR9708829A/pt not_active Application Discontinuation
- 1997-04-22 JP JP53879697A patent/JP4233115B2/ja not_active Expired - Fee Related
- 1997-04-22 PT PT97921045T patent/PT897386E/pt unknown
- 1997-04-22 SK SK1407-98A patent/SK282752B6/sk not_active IP Right Cessation
- 1997-04-22 TR TR1998/02156T patent/TR199802156T2/xx unknown
- 1997-04-22 DE DE69714987T patent/DE69714987T2/de not_active Expired - Lifetime
- 1997-04-23 MY MYPI97001748A patent/MY119011A/en unknown
-
1998
- 1998-10-14 RS YUP-448/98A patent/RS49718B/sr unknown
- 1998-10-19 IS IS4872A patent/IS1984B/is unknown
- 1998-10-21 NO NO19984903A patent/NO318850B1/no not_active IP Right Cessation
-
1999
- 1999-05-07 HK HK99102051A patent/HK1016978A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR006640A1 (es) | Procedimiento para la preparacion de una sal de magnesio de un sulfinil-heterociclo substituido | |
AR050267A1 (es) | Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
ES2162466T3 (es) | Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen. | |
AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
AR005277A1 (es) | Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. | |
AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
AR036598A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1 | |
RU98121016A (ru) | Способ получения магниевой соли замещенного сульфинил-гетероцикла | |
AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
AR052559A1 (es) | Derivados de pirazol para inhibir cdk's y gsk's | |
AR036042A1 (es) | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa | |
ES2191484T3 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. | |
YU160189A (sh) | Anelirani derivati tetrahidropiridinocetne kisline in postopki za njihovo pripravo | |
AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
ES2039242T3 (es) | Un procedimiento para la preparacion de nuevos derivados de piperidina. | |
AR048717A1 (es) | Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
AR012622A1 (es) | Inhibidores de proteasas, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos en la fabricacion de unmedicamento | |
AR034309A1 (es) | Derivados fenilsulfonilaminofenilamina, procedimiento para su preparacion, medicamentos y el uso de dichos derivados para la preparacion de medicamentos antivirales | |
AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
CO4810374A1 (es) | Nueva utilizacion de compuestos para actividad anti- pruritica | |
AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |